Regeneron Pharmaceuticals is a biopharmaceutical company that focuses on the discovery, development, and commercialization of innovative medicines for serious medical conditions. The company is renowned for its cutting-edge research in areas such as genetics, biochemistry, and biology, which has led to the development of a range of therapies for diseases including cancer, eye disorders, and inflammatory conditions. Regeneron's commitment to scientific advancement and collaboration propels its pipeline of novel treatments, aimed at improving patient outcomes and addressing unmet medical needs on a global scale. Read More
The global economy is currently grappling with a projected deceleration in GDP growth, a situation severely exacerbated by an unprecedented escalation of U.S. tariffs. These twin forces are creating a potent cocktail of stagflationary pressures, threatening to disrupt corporate supply chains, erode investor confidence, and reshape the landscape of
Regeneron's Phase 3 trials for cat and birch allergies show significant symptom relief and strong safety results, paving the way for future development.
In separate cat and birch allergen-challenge trials, single doses of allergen-specific antibody blockers significantly reduced allergy symptoms compared to placebo
TARRYTOWN, N.Y., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced today that it will now present at the Morgan Stanley 23rd Annual Global Healthcare Conference at 7:00 a.m. ET on Monday, September 8, 2025.
Sanofi's potential successor to Dupixent, amlitelimab, failed to meet investor expectations in a late-stage trial, raising doubts about its dermatology franchise.
As the Q2 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the immuno-oncology industry, including Regeneron (NASDAQ:REGN) and its peers.
Discover REGN, a top value investing stock. It boasts strong fundamentals, low P/E ratios, high profitability, and solid financial health, trading below its intrinsic worth.
Cemdisiran monotherapy, dosed subcutaneously every three months, met the primary and key secondary endpoints, showing a 2.3-point placebo-adjusted improvement in Myasthenia Gravis Activities of Daily Living (MG-ADL) total score
TARRYTOWN, N.Y., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has extended the target action dates to the fourth quarter of 2025 for two EYLEA HD® (aflibercept) Injection 8 mg regulatory submissions. This includes a Chemistry, Manufacturing and Controls (CMC) Prior-Approval Supplement (PAS) for the EYLEA HD prefilled syringe and a supplemental Biologics License Application (sBLA) seeking approval for both the treatment of macular edema following retinal vein occlusion (RVO) and the broadening of the dosing schedule to include every 4-week (monthly) dosing across approved indications.
Wall Street has set ambitious price targets for the stocks in this article.
While this suggests attractive upside potential, it’s important to remain skeptical because analysts face institutional pressures that can sometimes lead to overly optimistic forecasts.
